Dapsone-induced Methemoglobinemia in a Child with End-stage Renal Disease: A Brief Review

Area of Science:

• Nephrology
• Pharmacology
• Infectious Diseases

Background:

• Immunosuppressive therapy is crucial for managing renal transplant rejection and end-stage renal disease (ESRD).
• Prophylaxis against opportunistic infections like Pneumocystis jiroveci pneumonia is standard in immunosuppressed patients.
• Dapsone is a commonly used antibiotic for Pneumocystis jiroveci infection prophylaxis.

Observation:

• A pediatric patient with ESRD, undergoing immunosuppressive therapy post-renal transplant, presented with an unusual adverse event.
• The patient was receiving dapsone for Pneumocystis jiroveci infection prophylaxis at the time of the event.

Findings:

• The patient developed methemoglobinemia, a serious condition characterized by elevated levels of methemoglobin in the blood.
• This adverse event was temporally associated with dapsone administration, suggesting a potential drug-induced complication.

Implications:

• This case highlights a rare but significant adverse effect of dapsone in a vulnerable patient population.
• Clinicians should maintain a high index of suspicion for methemoglobinemia in immunosuppressed patients receiving dapsone.
• Further investigation into the risk factors and mechanisms of dapsone-induced methemoglobinemia in renal transplant recipients is warranted.